a:5:{s:8:"template";s:17037:" {{ keyword }}

";s:4:"text";s:3350:"About SciClone Pharmaceuticals International Ltd. SciClone Pharmaceuticals is a privately-owned specialty pharmaceutical company with a substantial commercial business in Greater China and a product portfolio focusing on oncology and infectious diseases. These include statements about the clinical activity of RRx-001, any additional equity investment by SciClone, or the receipt of future milestones and royalties from SciClone.

Anand Doobay The Hong Kong-based drugmaker said in an August regulatory filing that it was under investigation for potential Foreign Corrupt Practices Act violations. As an immunotherapeutic with a non-overlapping mechanism of action and the potential to convert "treatment-resistant" tumors into "treatment sensitive" tumors, RRx-001 may be used as monotherapy or in combination with chemotherapy, immunotherapy, radiation and targeted agents.

RRx-001 is currently a Phase 3 trial called REPLATINUM trial for the treatment of third-line and beyond SCLC. EpicentRx does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.SOURCE EpicentRx, Inc.; SciClone Pharmaceuticals International Ltd.Copyright © 2020 PR Newswire Association LLC. Simone Nadelhofer Although EpicentRx believes that it has a reasonable basis for forward-looking statements contained herein, they are based on current expectations about future events affecting EpicentRx and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. On Thursday, the Financial Times ran a cover story on the probe, which was followed by a New York Times story on Friday.

For more information regarding EpicentRx, go to: SciClone Pharmaceuticals is a privately-owned specialty pharmaceutical company with a substantial commercial business in This press release contains forward-looking statements. and Daniel Lucien Bühr EpicentRx's lead program is among a portfolio of novel dinitroazetidine-based drugs that downregulate CD47 – SIRPα to alter the tumor microenvironment and optimize immune responses as well as normalize the tumor vasculature for better drug and oxygen delivery, and has been tested in several clinical trials including an ongoing Phase 3 study in SCLC.

SciClone Pharmaceuticals International Ltd Baxter Discloses Possible Bribery in China 02 August 2013 At the moment, then, there are (at least) four investigations by Chinese authorities into foreign companies: Baxter, Sanofi, GSK and AstraZeneca. This small molecule drug acts to normalize the tumor microenvironment, activate the tumor associated macrophages (TAMs) of the innate immune system, and sensitize solid tumors to standard therapies," said RRx-001 is a well-tolerated next generation small molecule immunotherapeutic that targets the CD47 – SIRPα axis and repolarizes tumor associated macrophages (TAMs) and other immunosuppressive cells in the tumor microenvironment to an immunostimulatory phenotype as well as improves tumor blood flow to enhance oxygen supply and drug delivery.
";s:7:"keyword";s:42:"sciclone pharmaceuticals international ltd";s:5:"links";s:852:"Mens Rockabilly Clothing Wholesale, What Nationality Is Julia Zemiro, Salesforce Vs Cisco, Sulli Goblin Lyrics, Chippewa Lake Mi Directions, Digital Thermometer Not Turning On, Timothy Williams Cheers, ";s:7:"expired";i:-1;}